Business
CUMBERLAND PHARMACEUTICALS INC: Our business development team identifies, evaluates and negotiates product acquisition, licensing and co-promotion arrangements.
Revenue increased 17.6% to $44.5M, while Net income increased 56.2% to ($2.8M).
The read at a glance✓ Audited against SEC data
- Scale — FY2025 revenue $44.5MWatch
- Profitability — Net income ($2.8M)Watch
- Cash generation — Free cash flow $4.8MOK
- Accounting — Formula distress score · no manipulation flag · earnings quality greyWatch
- Insiders — 60 buys; 0 sells in 365 daysOK
- Capital — share repurchases were $263.5KNote
Where the revenue comes from
Fiscal 2025, as CUMBERLAND PHARMACEUTICALS INC reports it. History and quarterly detail are in the app.
- Product$40.4M
- Product - Other$4.1M
- Other$4.1M
- Product - Talicia$3.3M
Latest filings
- 8-K · Company announcement2026-08-28
- 10-Q · Quarterly report2026-08-07
- 8-K · Company announcement2026-08-04
- 8-K · Company announcement2026-07-13
- 8-K · Company announcement2026-07-01
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about CUMBERLAND PHARMACEUTICALS INC, every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.